Ziv-aflibercept

Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF) . Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases[1][2].

Product Specifications

CAS Number

[1609655-49-3]

UNSPSC

12352203

Target

VEGFR

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ziv-aflibercept.html

Purity

95.00

Solubility

10 mM in DMSO

Smiles

[Ziv-aflibercept]

Molecular Weight

(96.9 kDa)

References & Citations

[1]Malik D, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol. 2014 Jun;98 Suppl 1 (Suppl 1) :i11-16. |[2]de Oliveira Dias JR, et al. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. Int J Retina Vitreous. 2016 Feb 1;2:3.